AB
FATE icon

Amalgamated Bank’s Fate Therapeutics FATE Stock Holding History

Amalgamated Bank’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,417
Closed -$3K – 2028
2025
Q4 		$3K Buy
3,417
+505
+17% +$606 ﹤0.01% 2849
2025
Q3 		$4K Hold
2,912
– – ﹤0.01% 2830
2025
Q2 		$3K Hold
2,912
– – ﹤0.01% 2908
2025
Q1 		$2K Hold
2,912
– – ﹤0.01% 2836
2024
Q4 		$5K Hold
2,912
– – ﹤0.01% 2718
2024
Q3 		$10K Hold
2,912
– – ﹤0.01% 2444
2024
Q2 		$10K Hold
2,912
– – ﹤0.01% 2432
2024
Q1 		$21K Sell
2,912
-4,535
-61% -$28.1K ﹤0.01% 2102
2023
Q4 		$28K Sell
7,447
-867
-10% -$2.05K ﹤0.01% 2496
2023
Q3 		$18K Hold
8,314
– – ﹤0.01% 2702
2023
Q2 		$40K Sell
8,314
-3,320
-29% -$18.3K ﹤0.01% 2413
2023
Q1 		$66K Sell
11,634
-1,744
-13% -$10.5K ﹤0.01% 2191
2022
Q4 		$135K Hold
13,378
– – ﹤0.01% 2010
2022
Q3 		$300K Buy
13,378
+215
+2% +$6.21K ﹤0.01% 1674
2022
Q2 		$326K Sell
13,163
-123
-0.9% -$3.39K ﹤0.01% 1669
2022
Q1 		$515K Sell
13,286
-998
-7% -$38.6K ﹤0.01% 1533
2021
Q4 		$836K Sell
14,284
-152
-1% -$8.62K 0.01% 1333
2021
Q3 		$856K Sell
14,436
-705
-5% -$55.3K 0.01% 1321
2021
Q2 		$1.31M Buy
15,141
+4,300
+40% +$347K 0.01% 1151
2021
Q1 		$894K Sell
10,841
-354
-3% -$33.9K 0.03% 643
2020
Q4 		$1.02M Buy
11,195
+54
+0.5% +$3.35K 0.04% 523
2020
Q3 		$445K Buy
11,141
+1,116
+11% +$39K 0.02% 907
2020
Q2 		$344K Sell
10,025
-960
-9% -$28.6K 0.02% 1032
2020
Q1 		$244K Sell
10,985
-668
-6% -$16.9K 0.01% 1257
2019
Q4 		$228K Buy
+11,653
New +$185K ﹤0.01% 1571

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Bank's FATE Position: Q1 2026 in Review

Amalgamated Bank sold out of Fate Therapeutics (FATE) in Q1 2026, closing a stake of 3,417 shares — an estimated $3K sold.

Amalgamated Bank first reported a position in FATE in Q4 2019 and held it in 25 quarters. The position peaked at $1.31M in Q2 2021. 158 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Amalgamated Bank reported no remaining Fate Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 3,417 Fate Therapeutics shares in Q1 2026, an estimated $3K.
  • Amalgamated Bank first reported a position in Fate Therapeutics in Q4 2019 and held it in 25 quarters.
  • Amalgamated Bank's Fate Therapeutics position peaked at $1.31M in Q2 2021.
  • 158 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.